$ACRS

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the Leerink Partners 2026 Global Healthcare Conference. Dr. Neal Walker, CEO, and other senior leaders will host a fireside chat on March 10, 2026, at 1:40 PM EDT. A live webcast will be available on the company's website.

Aclaris Therapeutics, Inc. participated in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 to provide a strategic overview of its clinical trials and future plans. The company is advancing several drug candidates, including bosakitug and ATI-052 for atopic dermatitis and asthma, and ATI-2138, an ITK/JAK3 inhibitor, for potential use in alopecia and lichen planus. Aclaris aims for a "best-in-class" strategy, differentiating its offerings in a competitive market by focusing on superior efficacy and safety profiles, particularly with its selective ITK inhibitors.

The Atopic Dermatitis Market is projected to reach $31.68 billion by 2033, growing at a CAGR of 13.7% from 2025. This growth is driven by innovation in biologics and small molecules, expanding treatment access, and strong pipeline activity by dermatology-focused companies like Almirall, Aclaris Therapeutics, and Kiniksa Pharmaceuticals. Key trends include a shift towards targeted biologics, increasing emphasis on oral small molecules, and expansion of pediatric indications.

Aclaris Therapeutics has initiated a Phase 1b proof-of-concept trial for its novel bispecific antibody, ATI-052, in patients with moderate-to-severe atopic dermatitis (AD). This follows positive Phase 1a interim results showing a strong safety profile and extended pharmacokinetics. The company also plans to start a second Phase 1b POC trial in asthma this quarter, with top-line results from both expected in the second half of 2026.

WAYNE, Pa., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Aclaris Therapeutics, Inc. ( NASDAQ: ACRS ) , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris' Chief Executive Officer and ...